A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Talazoparib (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2018 Status changed from not yet recruiting to recruiting.
- 25 Apr 2018 Planned End Date changed from 25 Feb 2023 to 1 Dec 2023.